We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Answers Drugmakers’ Brexit Questions on Transfers, Relocations
EMA Answers Drugmakers’ Brexit Questions on Transfers, Relocations
The European Medicines Agency says marketing authorization holders must be based in the European Economic Area post-Brexit — and UK-based companies will likely need to transfer marketing authorizations to new addressees.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor